ProText Mobility, Inc. (TXTM)
USD 0.0
(-9.09%)
USD 0.0
(-9.09%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 62.41 Thousand USD | 622.04% |
| 2022 | 8644.00 USD | -87.7% |
| 2021 | 70.3 Thousand USD | -76.73% |
| 2020 | 302.15 Thousand USD | 1.21% |
| 2019 | 298.55 Thousand USD | -70.34% |
| 2018 | 1 Million USD | -33.24% |
| 2017 | 1.5 Million USD | -3.1% |
| 2016 | 1.55 Million USD | 0.0% |
| 2013 | 1.43 Million USD | -1.57% |
| 2012 | 1.45 Million USD | 45.7% |
| 2011 | 999.79 Thousand USD | -18.13% |
| 2010 | 1.22 Million USD | -44.56% |
| 2009 | 2.2 Million USD | 6.34% |
| 2008 | 2.07 Million USD | -24.39% |
| 2007 | 2.73 Million USD | 12.26% |
| 2006 | 2.44 Million USD | 308.36% |
| 2005 | 597.66 Thousand USD | 844.52% |
| 2004 | 63.27 Thousand USD | 186.8% |
| 2003 | 22.06 Thousand USD | -95.81% |
| 2002 | 526.32 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 69.67 Thousand USD | 11.64% |
| 2023 Q3 | 51.6 Thousand USD | 4.04% |
| 2023 Q2 | 49.6 Thousand USD | 122.58% |
| 2023 Q1 | 22.28 Thousand USD | 157.81% |
| 2023 Q4 | 62.41 Thousand USD | 20.94% |
| 2023 FY | 62.41 Thousand USD | 622.04% |
| 2022 Q1 | 39.05 Thousand USD | -44.45% |
| 2022 Q4 | 8644.00 USD | 0.0% |
| 2022 FY | 8644.00 USD | -87.7% |
| 2022 Q3 | - USD | 0.0% |
| 2021 Q3 | 70.3 Thousand USD | -8.96% |
| 2021 FY | 70.3 Thousand USD | -76.73% |
| 2021 Q4 | 70.3 Thousand USD | 0.0% |
| 2021 Q2 | 77.22 Thousand USD | -67.15% |
| 2021 Q1 | 235.05 Thousand USD | 0.0% |
| 2020 FY | 302.15 Thousand USD | 1.21% |
| 2019 FY | 298.55 Thousand USD | -70.34% |
| 2018 FY | 1 Million USD | -33.24% |
| 2017 FY | 1.5 Million USD | -3.1% |
| 2016 FY | 1.55 Million USD | 0.0% |
| 2014 Q3 | 1.42 Million USD | 0.25% |
| 2014 Q1 | 1.34 Million USD | -6.16% |
| 2014 Q2 | 1.41 Million USD | 5.29% |
| 2013 Q3 | 1.42 Million USD | 2.09% |
| 2013 FY | 1.43 Million USD | -1.57% |
| 2013 Q1 | 1.43 Million USD | -1.42% |
| 2013 Q4 | 1.43 Million USD | 0.48% |
| 2013 Q2 | 1.39 Million USD | -2.66% |
| 2012 FY | 1.45 Million USD | 45.7% |
| 2012 Q4 | 1.45 Million USD | 7.09% |
| 2012 Q3 | 1.36 Million USD | 9.09% |
| 2012 Q2 | 1.24 Million USD | 8.58% |
| 2012 Q1 | 1.14 Million USD | 14.86% |
| 2011 FY | 999.79 Thousand USD | -18.13% |
| 2011 Q4 | 999.79 Thousand USD | 14.01% |
| 2011 Q3 | 876.91 Thousand USD | 13.27% |
| 2011 Q2 | 774.15 Thousand USD | 5.12% |
| 2011 Q1 | 736.43 Thousand USD | -39.7% |
| 2010 FY | 1.22 Million USD | -44.56% |
| 2010 Q1 | 2.25 Million USD | 2.57% |
| 2010 Q2 | 1.76 Million USD | -21.68% |
| 2010 Q3 | 1.6 Million USD | -9.52% |
| 2010 Q4 | 1.22 Million USD | -23.74% |
| 2009 Q3 | 2.07 Million USD | -31.6% |
| 2009 FY | 2.2 Million USD | 6.34% |
| 2009 Q4 | 2.2 Million USD | 6.22% |
| 2009 Q2 | 3.03 Million USD | 12.94% |
| 2009 Q1 | 2.68 Million USD | 29.59% |
| 2008 Q4 | 2.07 Million USD | 22.44% |
| 2008 Q2 | 1.54 Million USD | 59.86% |
| 2008 Q1 | 967.35 Thousand USD | -64.69% |
| 2008 FY | 2.07 Million USD | -24.39% |
| 2008 Q3 | 1.69 Million USD | 9.41% |
| 2007 Q2 | 2.56 Million USD | 6.9% |
| 2007 Q1 | 2.4 Million USD | -1.6% |
| 2007 FY | 2.73 Million USD | 12.26% |
| 2007 Q4 | 2.73 Million USD | -0.27% |
| 2007 Q3 | 2.74 Million USD | 7.02% |
| 2006 Q3 | 2.8 Million USD | 87.97% |
| 2006 FY | 2.44 Million USD | 308.36% |
| 2006 Q2 | 1.49 Million USD | 7.26% |
| 2006 Q1 | 1.39 Million USD | 132.66% |
| 2006 Q4 | 2.44 Million USD | -12.94% |
| 2005 Q3 | 238.63 Thousand USD | 352.44% |
| 2005 Q1 | 60.62 Thousand USD | -4.2% |
| 2005 FY | 597.66 Thousand USD | 844.52% |
| 2005 Q4 | 597.66 Thousand USD | 150.45% |
| 2005 Q2 | 52.74 Thousand USD | -12.99% |
| 2004 Q4 | 63.27 Thousand USD | 248.02% |
| 2004 Q2 | 19.51 Thousand USD | -6.21% |
| 2004 Q1 | 20.81 Thousand USD | -5.67% |
| 2004 FY | 63.27 Thousand USD | 186.8% |
| 2004 Q3 | 18.18 Thousand USD | -6.84% |
| 2003 FY | 22.06 Thousand USD | -95.81% |
| 2003 Q2 | 449.06 Thousand USD | -0.26% |
| 2003 Q4 | 22.06 Thousand USD | -53.92% |
| 2003 Q3 | 47.87 Thousand USD | -89.34% |
| 2003 Q1 | 450.21 Thousand USD | 0.0% |
| 2002 FY | 526.32 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.849% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 98.486% |
| SQZ Biotechnologies Company | 27.47 Million USD | 99.773% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.856% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 99.79% |
| Mesoblast Limited | 118.7 Million USD | 99.947% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 93.418% |
| Genus plc | 233.1 Million USD | 99.973% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 97.87% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 95.355% |
| Marizyme, Inc. | 18.71 Million USD | 99.667% |
| ContraFect Corporation | 2.88 Million USD | 97.834% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 91.678% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | 53.934% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 95.685% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 97.317% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 98.897% |
| MultiCell Technologies, Inc. | 202.58 USD | -30709.063% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.891% |
| EV Biologics, Inc. | 1.49 Million USD | 95.825% |
| Q BioMed Inc. | 4.1 Million USD | 98.481% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 99.811% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 90.094% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 94.919% |
| Biomind Labs Inc. | 735.54 Thousand USD | 91.515% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.964% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 99.52% |
| Skye Bioscience, Inc. | 4.61 Million USD | 98.648% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 92.972% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | 55.897% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 98.937% |
| IMV Inc. | 28.88 Million USD | 99.784% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -142.673% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 97.236% |
| GB Sciences, Inc. | 1.75 Million USD | 96.452% |
| Alpha Cognition Inc. | 1.22 Million USD | 94.886% |
| HST Global, Inc. | 98.31 Thousand USD | 36.52% |
| CSL Limited | 12.18 Billion USD | 99.999% |
| Halberd Corporation | 150 Thousand USD | 58.391% |
| Enzolytics Inc. | 996.33 Thousand USD | 93.736% |
| Resverlogix Corp. | 6.49 Million USD | 99.038% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | 86.929% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | 75.581% |
| argenx SE | 20 Million USD | 99.688% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.863% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 97.696% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -510.396% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.985% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | 68.889% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 97.397% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | 72.78% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.908% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 97.938% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 82.649% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 99.693% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | 58.015% |
| BioStem Technologies, Inc. | 4.71 Million USD | 98.675% |
| ONE Bio Corp. | 19.71 Million USD | 99.683% |
| Reve Technologies, Inc. | 250.18 Thousand USD | 75.053% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | 74.906% |
| Agentix Corp. | 50 Thousand USD | -24.826% |
| LadRx Corporation | 33.6 Thousand USD | -85.72% |
| Cell Source, Inc. | 9.25 Million USD | 99.326% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 91.747% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 91.747% |
| NovAccess Global Inc. | 2.19 Million USD | 97.163% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 99.118% |
| Itoco Inc. | 228.37 Thousand USD | 72.671% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | 70.417% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 98.747% |
| Kadimastem Ltd | 891.22 Thousand USD | 92.997% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 84.469% |
| CytoDyn Inc. | 30.07 Million USD | 99.792% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | 87.112% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | 82.261% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 99.202% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | 49.051% |
| Rebus Holdings, Inc. | 310 Thousand USD | 79.867% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 98.682% |
| International Stem Cell Corporation | 4.17 Million USD | 98.506% |
| Bioxytran, Inc. | 1.92 Million USD | 96.758% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 97.138% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 99.249% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 99.273% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 95.988% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | 76.712% |
| Neutra Corp. | 54.15 Thousand USD | -15.247% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 96.589% |
| PureTech Health plc | 25.51 Million USD | 99.755% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 94.902% |
| IXICO plc | 472.02 Thousand USD | 86.778% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 99.597% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.9% |
| CSL Limited | 12.18 Billion USD | 99.999% |
| Cellectis S.A. | 92.77 Million USD | 99.933% |